As of right now the only things we have upcoming in the near future are the PII interim results of TPIV 200 in ovarian cancer and the start of the company sponsored PII in AML. Both of these were supposed to happen by the end of the year but the AML trial might be pushed out to 2020. We could get a pancreatic update but obviously that isn't scheduled. It's possible the company presents at ASH but that has not been confirmed and I don't know what they would present that we haven't already seen or don't already know about.
I'm still long but barring anything miraculous between now and Q2 of next year I don't see a massive uptick in share price. We will be at the mercy of the day traders. If Marker can't come up with non dilutive funding, which is probably a pipe dream at this point, then we're probably going to shafted with the next offering somewhere in this $4-$6 range. I can only hope they keep it on the smaller side and just take enough funding to cover the next year or so.
News 
Market Data 
Discover 
